Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 497, P. 154652 - 154652
Published: Aug. 8, 2024
Language: Английский
Cancer Cell, Journal Year: 2024, Volume and Issue: 42(4), P. 513 - 534
Published: April 1, 2024
Language: Английский
Citations
137
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Sept. 7, 2023
Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being common and aggressive type. Despite two decades of relentless pursuit in exploring novel therapeutic approaches for GBM, there is limited progress improving patients’ survival outcomes. Numerous obstacles impede effective treatment including immunosuppressive tumor microenvironment (TME), blood-brain barrier, extensive heterogeneity. these challenges, immunotherapies emerging as a promising avenue that may offer new hope gliomas. There four main types gliomas, immune checkpoint blockades, chimeric antigen receptor T-cell therapies, vaccines, oncolytic viruses. In addition, gene therapy, bispecific antibody combine therapy also briefly introduced this review. The significant role TME process has been emphasized many studies. Although immunotherapy enormous effort required to overcome existing barriers its success. Owing rapid development increasing attention paid article aims review recent advances
Language: Английский
Citations
91
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Oct. 18, 2024
Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment therapy, only a minority patients exhibit positive response to it. In with solid tumors, those who respond well typically demonstrate an active profile referred as "hot" (immune-inflamed) phenotype. On other hand, non-responsive may distinct "cold" (immune-desert) phenotype, differing from features tumors. Additionally, there is more nuanced "excluded" positioned between and categories, known type. Effective differentiation understanding intrinsic factors, characteristics, TME, external factors are critical for predicting results. It widely accepted that therapy exerts profound effect on limited efficacy against or "altered" necessitating combinations therapeutic modalities enhance cell infiltration into tissue convert tumors ones. Therefore, aligning traits this review systematically delineates respective influencing extensively discusses varied approaches drug targets based assess efficacy.
Language: Английский
Citations
68
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Jan. 29, 2024
Cancer, a disease that modern medicine has not fully understood and conquered, with its high incidence mortality, deprives countless patients of health even life. According to global cancer statistics, there were an estimated 19.3 million new cases nearly 10 deaths in 2020, the age-standardized mortality rates 201.0 100.7 per 100,000, respectively. Although remarkable advancements have been made therapeutic strategies recently, overall prognosis remains optimistic. Consequently, are still many severe challenges be faced difficult problems solved therapy today. Epigallocatechin gallate (EGCG), natural polyphenol extracted from tea leaves, received much attention for antitumor effects. Accumulating investigations confirmed EGCG can inhibit tumorigenesis progression by triggering apoptosis, suppressing proliferation, invasion, migration, altering tumor epigenetic modification, overcoming chemotherapy resistance. Nevertheless, regulatory roles biomolecular mechanisms immune microenvironment, metabolic immunotherapy remain obscure. In this article, we summarized most recent updates about effects on microenvironment (TME), reprogramming, anti-cancer immunotherapy. The results demonstrated promote response cytotoxic lymphocytes dendritic cells (DCs), attenuate immunosuppression myeloid-derived suppressor (MDSCs) T (Tregs), tumor-promoting functions tumor-associated macrophages (TAMs), neutrophils (TANs), various stromal including cancer-associated fibroblasts (CAFs), endothelial (ECs), stellate cells, mesenchymal stem/stromal (MSCs). Additionally, suppress multiple reprogramming pathways, glucose uptake, aerobic glycolysis, glutamine metabolism, fatty acid anabolism, nucleotide synthesis. Finally, EGCG, as immunomodulator checkpoint blockade, enhance immunotherapeutic efficacy may promising candidate conclusion, plays versatile TME which provides novel insights combined
Language: Английский
Citations
19
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Nov. 15, 2024
Normal life requires cell division to produce new cells, but death is necessary maintain balance. Dysregulation of can lead the survival and proliferation abnormal promoting tumor development. Unlike apoptosis, necrosis, autophagy, newly recognized forms regulated (RCD) cuproptosis, ferroptosis, PANoptosis provide novel therapeutic strategies for treatment. Increasing research indicates that immune cells mediated by these discovered regulate microenvironment (TME) influence effectiveness immunotherapy. This review primarily elucidates molecular mechanisms their complex effects on TME. also summarizes exploration nanoparticle applications in therapy based vivo vitro evidence derived from induction or inhibition RCD pathways.
Language: Английский
Citations
17
Angewandte Chemie International Edition, Journal Year: 2024, Volume and Issue: 63(22)
Published: March 29, 2024
The immune checkpoint blockade strategy has improved the survival rate of late-stage lung cancer patients. However, low response limits immunotherapy efficiency. Here, we report a ROS-responsive Fe
Language: Английский
Citations
15
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 142 - 142
Published: Jan. 21, 2025
Glioblastoma’s (GB) complex tumor microenvironment (TME) promotes its progression and resistance to therapy. A critical component of TME is the extracellular matrix (ECM), which plays a pivotal role in promoting tumor’s invasive behavior aggressiveness. Nanotechnology holds significant promise for GB treatment, with potential address challenges posed by both blood-brain barrier ECM. By enabling targeted delivery therapeutic diagnostic agents, nanotechnology offers prospect improving treatment efficacy accuracy at site. This review provides comprehensive exploration GB, including epidemiology, classification, current strategies, alongside intricacies TME. It highlights nanotechnology-based focusing on nanoparticle formulations such as liposomes, polymeric nanoparticles, gold have shown Furthermore, it explores how different emerging strategies modulate ECM overcome high density, restricts drug distribution within tumors. emphasizing intersection ECM, this underscores an innovative approach advancing treatment. addresses limitations therapies, identifies new research avenues, emphasizes improve patient outcomes.
Language: Английский
Citations
2
Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101606 - 101606
Published: Feb. 27, 2025
Language: Английский
Citations
2
Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217696 - 217696
Published: April 1, 2025
Language: Английский
Citations
2
Expert Opinion on Drug Delivery, Journal Year: 2023, Volume and Issue: 20(11), P. 1623 - 1642
Published: Nov. 2, 2023
Tumors pose a significant global economic and health burden, with conventional cancer treatments lacking tumor specificity, leading to limited efficiency undesirable side effects. Targeted therapy is imminent. Tumor cells produce lactate hydrogen ions (H
Language: Английский
Citations
22